Rapport Therapeutics’ IPO came with a concurrent private placement that boosted the biotech’s cash haul. The new capital will support clinical development of a lead drug with a novel approach to focal epilepsy, a form of the disorder that affects 1.8 million people in the U.S.

The post Rapport’s Stock Market Debut Reaps $154M as Novel Epilepsy Med Heads for Mid-Stage Test appeared first on MedCity News.

Rapport Therapeutics’ lead program could offer more targeted epilepsy treatment compared to currently available anti-seizure medications, which introduce many side effects. The IPO will support plans to develop the oral small molecule in focal epilepsy as well as peripheral neuropathic pain and bipolar disorder.

The post CNS-Focused Rapport Therapeutics Preps IPO to Back Phase 2-Ready Epilepsy Drug appeared first on MedCity News.

Longboard Pharmaceuticals’ epilepsy drug candidate bexicaserin met the main efficacy goal of its Phase 1b/2a study along with safety data suggesting a potential edge over current treatments. With Longboard now preparing to advance to Phase 3 testing, its stock price soared more than 300%.

The post Longboard Pharma Trial Data Show How It Could Stand Out in the Epilepsy Field appeared first on MedCity News.

Marinus Pharmaceuticals drug Ztalmy is now FDA approved for treating the seizures in patients who have CDKL5 deficiency, an inherited form of epilepsy. The drug is the first approved treatment for the rare disorder and it’s also Marinus’s first approved product.

The post FDA approves Marinus Pharma drug for rare, genetic form of epilepsy appeared first on MedCity News.

Neuroscience drug developer Biohaven Pharmaceuticals is expanding its pipeline to include epilepsy and spinal muscular atrophy. The drug developer is acquiring Channel Bioscience and licensing global rights to a Phase 3-ready drug from Bristol Myers Squibb.

The post Biohaven pays $100M for epilepsy drug prospect; strikes deal for BMS muscle med appeared first on MedCity News.

Epilepsy is a small part of UCB’s neurology pipeline, but its proposed Zogenix acquisition would broaden the Belgium-based drugmaker’s ability to address that market. Zogenix’s Fintepla is approved in the U.S. and Europe for a rare type of epilepsy called Dravet syndrome, and is in development for other rare epilepsies.

The post UCB is expanding its reach in epilepsy with $1.9B Zogenix acquisition appeared first on MedCity News.

Ovid Therapeutics is acquiring global rights to AstraZeneca molecules that address a novel target to treat epilepsy. The AstraZeneca deal comes 10 months after Takeda Pharmaceutical paid $196 million up front to acquire Ovid’s rights to a Phase 3 ready molecule for two rare forms of epilepsy.

The post Ovid Therapeutics adds to epilepsy drug pipeline with new AstraZeneca alliance appeared first on MedCity News.

Vagus nerve stimulation devices still have a long way to go, but the therapeutic potential of the vagus nerve, the advent of AI and machine learning in healthcare and the opportunity to establish truly personalized digital medicine are enough to warrant further exploration into VNS.

The post The role of AI in advancing neuromodulation treatment for epilepsy appeared first on MedCity News.

The algorithm maps interactions between different areas of the brain, which can help guide the placement of electrodes for stimulating devices to treat brain diseases, like epilepsy, and movement disorders.

The post Mayo Clinic, Google develop AI algorithm to enhance electrical brain stimulation appeared first on MedCity News.

Takeda Pharmaceutical gains full rights to a small molecule that has shown promise treating seizures in several rare forms of epilepsy. Meanwhile, Ovid Therapeutics gains cash to support its pipeline of neurological disease drug candidates.

The post Takeda to pay Ovid $196M for full rights to Phase 3-ready epilepsy drug appeared first on MedCity News.

The data from a Phase II pilot and an extension study of soticlestat, also known as OV935 or TAK-935, showed short- and long-term reductions of seizure frequency in patients with CDKL5 deficiency disorder and Dup15q syndrome.

The post Ovid drug reduces seizure frequency in two rare forms of epilepsy, according to early Phase II data appeared first on MedCity News.

The European Commission approved GW Pharma’s Epidyolex as a treatment for seizures in two rare and severe forms of epilepsy. The drug won FDA approval last year.

The post GW Pharmaceuticals’ cannabis-derived epilepsy drug wins European approval appeared first on MedCity News.

The drug showed positive results in a 210-patient study in patients experiencing treatment-resistant seizures from tuberous sclerosis complex, a rare form of epilepsy.

The post GW’s cannabinoid-based Epidiolex scores another Phase III epilepsy victory appeared first on MedCity News.

The company’s cell phone-sized device delivers low-level electric stimulation to the trigeminal nerve through a patch placed on a patient’s forehead. 

The post NeuroSigma wins FDA nod for first non-drug ADHD treatment appeared first on MedCity News.

Cerevel will take on several clinical and preclinical candidates from Pfizer, which divested from neuroscience this year and will take a 25 percent stake in the new company.

The post Bain invests $350M in new company Cerevel to develop Pfizer’s neuroscience pipeline appeared first on MedCity News.

System1 Biosciences’ platform combines stem cell lines from patients with brain diseases with a three-dimensional in vitro system and data analytics.

The post System1 Biosciences raises $25M in Series A round for neurotherapeutics discovery platform appeared first on MedCity News.

The FDA approved the cannabis-based drug for treating seizures in two severe forms of epilepsy.

The post GW Pharmaceuticals gets first FDA approval for CBD-based drug appeared first on MedCity News.

Bloom Science plans to have its proprietary gut bacteria in the clinic for hard-to-treat patients in the next 12-18 months.

The post Start-up plans to target epilepsy using gut microbiota appeared first on MedCity News.

By passively collecting seizure data, Empatica’s device could help patients share medical information with clinicians and make that data easier to manage.

The post A wearable using AI to identify severe seizures and warn caregivers gains FDA approval appeared first on MedCity News.

Medical researchers frequently spend the majority of their time formatting research data and 10 percent of their time actually using it. Blackfynn hopes its platform will aid translational research and therapeutic product development.

The post Blackfynn gets $2.3M, adds partners for data integration tools to accelerate neuroscience research appeared first on MedCity News.

NeuroVice’s device is designed to provide a safe way to protect tongues and minimize salivation during seizures.

The post This entrepreneur’s device is designed to protect the tongue during a seizure appeared first on MedCity News.

The goal is to track the severity and length of the seizure using sensors such as an accelerometer and a gyroscope as well as a memory test when the user comes out of the event.

The post Smart watches are opening up seizure tracking (Updated) appeared first on MedCity News.

Aprecia Pharmaceuticals is getting closer to commercializing SPRITAM, its 3D printed formulation of levetiracetam, which is a well-established medication used by patients with epilepsy.

The post Aprecia Pharmaceuticals brings in $35M to move forward with 3D printed dissolving drug pipeline appeared first on MedCity News.

The post Convenient timing, Shkreli: Turing’s epilepsy drug gets fast-tracked by FDA appeared first on MedCity News.

The post Turing announces first IND application for new brain disorder drug (post-Daraprim pricing controversy) appeared first on MedCity News.

The post Epilepsy device developer NeuroSigma has withdrawn its $50M IPO plans appeared first on MedCity News.

The post Wearables help manage neurological disorders, predict symptoms appeared first on MedCity News.

The post FDA approved first 3D printed drug. What are other applications for this technology? appeared first on MedCity News.

The post Morning Read: FDA approves the first 3D printed drug, OraSure Ebola test gets FDA Emergency Use Authorization appeared first on MedCity News.

The post Implantable brain device could restore lost memories, help create new ones appeared first on MedCity News.